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This study was a prospective, parallel-group, randomi-
zed, double-blind, vehicle-controlled, multi-centre clini-
cal trial to compare the efficacy of topical sertaconazole 
2% cream with vehicle in reducing chronic pruritus in 
subjects with atopic dermatitis, and to assess its safety 
and local tolerability. A total of 70 subjects applied either 
of the 2 treatments twice daily for a period of 4 weeks on 
affected, itchy skin areas. Treatment efficacy was eva-
luated primarily considering the item itch intensity on 
a 5-point verbal rating scale. Insomnia, state of atopic 
dermatitis (Scoring Atopic Dermatitis; SCORAD), qua-
lity of life and therapy benefit were also assessed. No 
significant difference between active treatment and ve-
hicle was found at any of the time-points for any of the 
investigated parameters. Under the experimental condi-
tions of the study, sertaconazole 2% cream did not exert 
anti-pruritic effects that were better than vehicle in sub-
jects with atopic dermatitis who had chronic pruritus. 
Trial registration ClinicalTrials.gov #NCT01792713. Key 
words: sertaconazole; pruritus; itch; atopic dermatitis.
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Atopic dermatitis (AD), one of the most pruritic skin di-
seases (1, 2), is a common disorder affecting 15–30% of 
children and 2–10% of adults in industrialized countries 
(3). Pruritus, the unpleasant sensation that leads to a de-
sire to scratch (4), is the most important clinical symptom 
of AD (5, 6) with a prevalence of up to 100% in this 
disease (7). The exact pathophysiology of itch in AD is 
not yet fully understood (8). Studies have demonstrated 
that mechanisms such as increased density of cutaneous 
nerve fibres participate in the induction and maintenance 
of this troublesome and disabling symptom, in addition 
to various receptors (cold receptor TRPA1, histamine 4 
receptor, proteinase activated receptor 2/Mas-related G 
protein receptor) and central and peripheral mediators, 
e.g. histamine, nerve growth factor (NGF), substance 
P (SP), proteases, and cytokines/chemokines (thymic 
stromal lymphopoietin (TSLP), interleukin (IL) -2, IL-4, 
IL-13, prostaglandin E2 and IL-31) (1, 7-9). In severe 
cases of AD, subjects scratch the involved skin areas until 
they bleed (1). This worsens the skin condition, resulting 
in a vicious itch-scratch cycle, which severely affects 
the quality of life of subjects and their families (6). Itch 
management is, therefore, one of the most important is-
sues in the treatment of AD (10). There is no generally 
established therapy for itch in AD. Hence, atopic pruritus 
is usually treated with a tailored approach (11), either 
with moisturizers or with topical and systemic immu-
nosuppressants (12). Although such therapies generally 
have a good safety profile, better itch-specific treatment 
options are needed. 
Systemic and/or topical antimycotics of the imidazole 
type have been reported to be effective in AD (13–15). 
Their fungistatic or fungicidal effects can explain this 
as fungi, such as Malassezia furfur, are involved in 
AD. However, direct immunomodulatory effects have 
also been reported to be responsible for their efficacy 
in AD (15). Sertaconazole nitrate is a well-established, 
well-tolerated, commercially available (Dermofix®, 
Ertaczo™, Ginedermofix®, Monazol, Mykosert® or 
Zalain®) imidazole antifungal agent, which also exerts 
anti-bacterial action (16). Sertaconazole nitrate has been 
shown to reduce the release of cytokines from activated 
lymphocytes and to mitigate inflammation in animal 
models of irritant contact dermatitis and neurogenic 
inflammation (17). Furthermore, sertaconazole repor-
tedly inhibits contact hypersensitivity and scratching 
responses in a murine model of substance P-induced 
pruritus, indicating that topical administration may 
result in an efficacious anti-inflammatory activity in a 
spectrum of cutaneous inflammation models and itch 
(17). Kaur et al. (18) have shown that sertaconazole 
mediates its anti-itch effects by increasing prostaglan-
din D2 levels in mast cells and macrophages through 
induction of the p38 mitogen-activated protein kinase 
pathway. Prostaglandin D2 is known to have anti-
pruritic activity by suppressing histamine release (19). 
Finally, human studies in fungal infections reported 
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anti-pruritic effects from antimycotic treatment with 
sertaconazole (20–22). Therefore, sertaconazole with 
its positive safety profile (16) and its anti-inflammatory 
and anti-pruritic properties could be a possible solution 
to address pruritus in AD. However, clinical studies 
evaluating its anti-pruritic action in AD are sparse 
and, as yet, there are no published reports of controlled 
studies. Thus, the aim of this study was to close this 
gap, by comparing the efficacy of topical sertaconazole 
2% cream with vehicle in reducing chronic pruritus in 




This was a prospective, randomized (1:1), double-blind, 
vehicle-controlled, parallel-group, phase-II clinical trial con-
ducted at 2 sites in Germany (Center for Chronic Pruritus, 
Department of Dermatology, University Hospital Münster; 
Allergie-Centrum-Charité, Department of Dermatology and 
Allergy, Charité –Universitätsmedizin Berlin, Germany). All 
subjects gave written informed consent. The ethics commit-
tee at the central coordinating centre (Münster) and at the 
participating site (Berlin) both approved the trial. The trial is 
registered at the US National Institutes of Health (ClinicalTri-
als.gov) #NCT01792713 and at the European Union Clinical 
Trial Register.
Study population and treatment
Over a period of 11 months, 70 randomly (1:1) selected subjects 
(30 males, 40 females, 18–75 years, mean age 34.1 (± 14.7) 
years) with pruritus (> 6 weeks, visual analogue scale (VAS) 
≥ 7, (VAS 0–10) during the last 2 days before visit 1; verbal 
rating scale (VRS) ≥ 3) due to AD (Scoring Atopic Dermatitis; 
SCORAD ≤ 40) were included in the study. Subjects showing 
unstable or uncontrolled significant medical conditions, infec-
tions, addiction to alcohol or/and drugs, dermatological abnor-
malities, allergy to any of the treatment’s ingredients, participa-
tion in another clinical study, pregnancy or lactation or using 
therapies up to 2 or 4 weeks before onset of the study, which 
could influence its outcome (antihistamines, corticosteroids, 
immunomodulators, naltrexone, antidepressants, immunosup-
pressants, topical calcineurin inhibitors, topical antibiotics, 
antiseptics) were excluded from participation in this trial. 
Thirty-two subjects were treated with sertaconazole 2% 
cream and 38 with the cream’s vehicle (cream manufactured 
by the sponsor to match exactly appearance, odour and con-
sistency of the active cream) (Fig. 1). To ensure full blinding 
(assessors, care-givers, subjects), active and vehicle creams 
were both in neutral tubes and were randomized, labelled and 
delivered directly to the sites by a clinical services provider. 
In the centres, investigators chose a kit at random and after 
recording the number in the case report form it was given to 
the subject. Treatment was carried out twice daily, as indicated 
for the commercial cream Mykosert® (Dr. R. Pfleger Chemische 
Fabrik GmbH, Bamberg, Germany), during 4 weeks on affected 
itchy skin areas determined by the investigator, followed by a 
2-week treatment-free wash-out period. Subjects were allowed 
to use moisturizing cream (Excipial® Hydrocreme (Galderma- 
Spirig, Egerkingen, Switzerland)) with no additional therapy 
during the whole study. Adherence to treatment was assessed by 
collecting and weighing the treatment tubes at each subject visit. 
Study outcomes
The primary efficacy success was defined as ≥ 2 grades reduc-
tion in intensity of pruritus between baseline and week 4, as eva-
luated on a 5-point VRS, which was part of the patient’s global 
assessment (PGA) questionnaire. The subject answered this at 
each visit under the supervision of the investigator. Further ef-
ficacy variables were: intensity of pruritus and insomnia both on 
a VAS, state of atopic dermatitis (SCORAD, Eczema Area and 
Severity Index (EASI)) and of quality of life (Dermatological 
Life Quality Index (DLQI)). The Patients Benefit Index (PBI) 
questionnaire was used to evaluate the subjects’ appreciation 
of the treatment benefits vs. baseline, and featured 27 items. 
Each of the 27 items had to be answered as not at all, slightly, 
moderately, quite a lot or as very much. Skin barrier function 
(transepidermal water loss (TEWL)), mycological evaluation 
of skin surface, adverse events, vital signs and blood laboratory 
parameters were also assessed during the course of the study. 
All scales used are generally recognized as reliable, accurate 
and relevant for subjects with atopic dermatitis (6, 23, 24). 
Statistical methods
To achieve a ≥ 2 point decrease in pruritus intensity during treat-
ment in 60% of the active treated and in 30% of the vehicle-treated 
subjects, with a statistical power of ≥ 80% and a significance 
level at p ≤ 0.05%, the sample size was estimated at 40 subjects 
per group (due to recruiting difficulties a final total of 70 subjects 
was included in the study). The null hypothesis was defined as 
the success/failure ratio in both groups being the same. Statistical 
testing was conducted with a 2-sided χ2 test with Yates corrections. 
Statistical analysis of the secondary parameters (mean intensity of 
itch (VAS) and mean SCORAD) was conducted via analysis of co-
variance (ANCOVA) with baseline as a covariate and treatment as 
a factor. For EASI, statistical analysis was waived before outcome 
results were available, because at evaluation it appeared that the 
2 centres performed the EASI assessments in a different manner. 
Efficacy data were analysed at each visit based on the per-protocol 
(PP) population, excluding major deviations that were identified 
during a blind review of the data. In addition, an intention-to-treat 
(ITT) analysis was performed on all randomized subjects after 
inputting missing data using the last observation carried forward 
(ITT-LOCF). The Safety Population was defined as comprising 
the ITT-LOCF population. All safety data were summarized based 
on the Safety Population. 
Enrollment Assessed for eligibility (n=71)
Excluded (n=1)
lNot meeting inclusion criteria (n=1)
Allocated to active/ITT active (n=32)
lReceived allocated intervention (n=32)
Allocated to vehicle/ITT active (n=38)
lReceived allocated intervention (n=38)
Allocation
Discontinued intervention (worsening) (n=5)
Excluded (major protocol deviations (n=3)
Lost to follow-up (n=2)
Discontinued intervention (worsening) (n=4)
Excluded (major protocol deviations (n=3)
Follow-up
Analysed/PP (n=24) Analysed/PP (n=29)
Randomized (n=70)
Analysis
Fig. 1. Progress of all subjects through the trial. PP: per-protocol population.
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RESULTS
Efficacy 
Between February and December 2013 a total of 71 
subjects was screened for eligibility (Fig. 1). Seventy 
subjects met the eligibility criteria (ITT-LOCF) and 
were randomized either to active treatment (n = 32) or 
to vehicle (n = 38) (Fig. 1). Among these subjects, 17 
presented major protocol deviations (omission of pru-
ritus assessments, interfering concomitant treatments, 
visits outside the window foreseen). Thus, the remain-
ing 53 subjects composed the PP population (n = 24 ac-
tive treated, n = 29 vehicle treated). Demographics and 
baseline clinical characteristics were similar in both 
groups (Table I). No differences regarding compliance 
were apparent between treatments or between centres. 
In the ITT-LOCF population (Table II), a total of 5 
subjects (16%) in the active group and 8 subjects (21%) 
in the vehicle group achieved the primary objective of 
2 grades reduction in itch intensity (VRS) between ba-
seline (visit 1) and week 4 (visit 3) (p = 0.78). Between 
baseline and week 2 (visit 2), 5 subjects (16%) in the 
active and 4 (11%) in the vehicle group achieved the 
targeted reduction (p = 0.78), and between baseline and 
week 6 (visit 4), 7 (26%) active treated subjects and 5 
(16%) receiving vehicle achieved 2 grades reduction 
(p = 0.51). Looking at only one grade reduction (Table 
II) in itch intensity (VRS) between visits 1 and 3, again 
no statistically significant differences between active 
treatment (n = 7, 39%) and vehicle (n = 11, 52%) were 
found (p = 0.62), and the same was observed between 
visits 1 and 2 (p = 0.56) and between visits 1 and 4 
(p = 0.25). The overall results were similar in the PP po-
pulation (Table SI1) and when comparing both centres.
With regard to the secondary criteria, pruritus inten-
sity, as evaluated by VAS, decreased during the study 
slightly more in the active group (ITT-LOCF: 3.3 cm; 
PP 3.5 cm) than in the vehicle group (ITT-LOCF 2.2 
cm; PP 2.1 cm) (Tables II and SI1). However, these dif-
ferences were not statistically significant (ITT-LOCF 
p = 0.101; PP p = 0.09) (Tables II and SI1). Similarly, 
during the course of the study, insomnia rates (VAS) 
(only the PP population was considered) also decreased 
slightly, but not significantly, more in the active (from 
7.8 ± 0.7 cm to 3.2 ± 2.1 cm) than in the vehicle group 
(from 5.7 ± 2.6 cm to 3.7 ± 2.7 cm) (Table SI1). 
SCORAD remained stable over the study duration 
without statistically significant differences between 
active and vehicle, either at visit 3 (ITT-LOCF: p = 0.21, 
PP: p = 0.58) or at visit 4 (ITT-LOCF: p = 0.25, PP: 
p = 0.18) (Tables II and SI1). 
The continuous data evaluation of the quality of 
life (DLQI) values, which were analysed only in the 
PP population, decreased in the active group by 3.1 
(from 9.3 ± 4.2 to 6.2 ± 4.9) and in the vehicle group by 
approximately 4.2 (from 11.4 ± 6.3 to 7.2 ± 5.6) scores 
(Table SI1). In the same way, the categorical analysis of 
the DLQI (sum of the percentages of ‘’not at all’’ and 
‘’little’’ effect on subject’s life) increased from 13% 
(visit 1) to 44% (visit 3) in the active group and from 
21% (visit 1) to 48% (visit 3) in the vehicle group. 
The possible benefit of the therapy, as evaluated by 
the subject (PBI: Patient Benefit Index), showed that at 
the end of the treatment (visit 3), almost all questions 
were answered with ‘’Treatment helped not at all’’ by 
both groups. The cosmetic items evaluated (desqua-
mation, feeling of tenseness and burning sensation) 
remained stable during the study, with the exception of 
skin roughness, which showed a tendency to decrease 
(from 5.2 ± 2.4 at visit 1 to 2.7 ± 0.9 at visit 4) in the 
active group (Table SI1).
During the course of the study, TEWL of lesional and 
non-lesional skin remained stable in both groups (ac-
tive and vehicle) including the treatment-free washout 
phase (Table SI1). 
Overall, the results also remained the same when 
analysing all primary and secondary efficacy parameters 
for the 2 centres individually. No significant difference 
in treating pruritus in subjects with mild to moderate AD 
could be revealed between the sertaco-
nazole 2% cream and the vehicle cream. 
Safety
No safety issues were identified for 
either treatment during the study dura-
tion. The skin barrier function was not 
significantly influenced by the treat-
ments. A total of 35 subjects (active 
16, vehicle 19) reported 52 (active 25, 
vehicle 27) adverse events during the 
treatment phase. Thirty-three of these 
adverse events were dermatological 
(mostly AD worsening), of which 28 
could be related to the treatments (active 
Table I. Subject demographics and atopic dermatitis (AD) characteristics
Characteristic
Active Vehicle
ITT PP ITT PP
Total, n 32 24 38 29
Female, n (%) 16 (50) 13 (54) 24 (63) 17 (59)
Age, mean (SD) 37 (16.3) 36.7 (16.1) 31.7 (12.8) 31.7 (13.1)
AD family history, n (%) 16 (50) 10 (42) 20 (53) 16 (55)
Asthma as child, n (%) 8 (25) 6 (25) 16 (42) 11 (38)
Chronic pruritus, n (%) 32 (100) 24 (100) 38 (100) 29 (100)
Allergic rhinitis, n (%) 21 (66) 17 (71) 24 (63) 20 (69)
Xerosis/dry skin, n (%) 32 (100) 24 (100) 37 (97) 28 (97)
Mycological evaluation, positive, n 0 0 1 0
Age at first appearance, mean (SD)a 9 (19.1) 6.9 (17.8) 6.8 (15.5) 5.7 (14.8)
AD relapses during the last year, mean (SD) 7.6 (5.7) 6.3 (4.9) 9.1 (8.2) 10 (8.9)
aAge of the subject at first appearance of atopic dermatitis symptoms.
SD: standard deviation; ITT: intention-to-treat population; PP: per-protocol population.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2268
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15, vehicle 13). Finally, no differences between the 2 
groups or a trend concerning concomitant medication 
used to treat AD or adverse events during the study were 
apparent. 
DISCUSSION
The present study was designed with the main ob-
jective of demonstrating the anti-pruritic effect of 
sertaconazole 2% cream vs. vehicle in subjects with 
AD who had severe, chronic pruritus. The study failed 
to confirm this hypothesis. Under the experimental 
conditions of the study, the investigated sertaconazole 
2% cream showed a small anti-pruritic effect, which 
was not significantly different from that of the vehicle 
treatment. Of the criteria assessed, only the items itch 
intensity and insomnia (both VAS) and skin roughness 
(VRS) showed a tendency for a possibly stronger ef-
fect of sertaconazole. However, these effects achieved 
no significance vs. vehicle (Table SI1). In the case of 
SCORAD, the clinically meaningful decrease of at 
least 4 points (25) was reached only with the vehicle 
treatment without clinical significance vs. the active 
therapy. The fact that TEWL remained stable during 
the whole study in both lesional and non-lesional skin 
indicated that neither treatment influenced the skin 
barrier function (26). 
Similar observations were also made in 2 other clini-
cal studies in which a topical azole was either added 
or compared with hydrocortisone 1%. Wong et al. (27) 
found that the addition of an antifungal ointment (mi-
conazole cream) to 1% hydrocortisone cream did not 
add any benefit to the topical corticosteroid treatment 
in flexural AD. More recently, Saki et al. (28) compa-
red the effect of topical sertaconazole 2% cream and 
hydrocortisone 1% ointment in the treatment of AD in 
a double-blind bilateral study with 45 subjects aged 
6 months to 32 years. The duration of treatment was 
4 weeks. A modified SCORAD score was applied to 
assess the severity of the disease before and after tre-
atment. This study also found no significant difference 
between the 2 drugs in decreasing single symptoms, 
such as pruritus or erythema, i.e. both drugs improved 
the symptoms to the same extent. However, sertacona-
zole was significantly better in decreasing the total AD 
score (p = 0.023). Besides the fact that this study had a 
different design from ours (bilateral), subjects had to 
discontinue any other topical or systemic preparation, 
including basic emollients, which could be a possible 
explanation for the more positive outcome.
One could argue that, in our study, due to the stable, 
non-inflammatory state of AD at inclusion, it was dif-
ficult to significantly influence the scores. In addition, 
subjects were allowed to use a basic emollient cream 
(Excipial® Hydrocreme) ad libitum during the whole 
Table II. Efficacy results and evolution of the main criterion (itch intensity from verbal rating scale) from day 0 to day 42 in the intention-












1 Active 0 (0) 0 (0) 1 (3) 0 (0)
Vehicle 0 (0) 0 (0) 1 (3) 0 (0)
2 Active 0 (0) 4 (13) 6 (19) 7 (26)
Vehicle 0 (0) 7 (18) 10 (26) 6 (19)
3 Active 3 (9) 8 (25) 9 (28) 12 (44)
Vehicle 10 (26) 8 (21) 6 (16) 9 (28)
4 Active 24 (75) 11 (34) 9 (28) 5 (19)
Vehicle 22 (58) 15 (39) 16 (42) 10 (31)
5 Active 5 (16) 9 (28) 7 (22) 3 (11)
Vehicle 6 (16) 8 (21) 5 (13) 6 (19)
Primary criterion itch intensitya
VRS ≥ 2, n (%) (p) Active 5 (16) p = 0.7822 5 (16) p = 0.7847 7 (26) p = 0.517Vehicle 4 (11) 8 (21) 5 (16)
VRS ≥1, n (%) (p)
 
Active 12 (38) p = 0.7123 15 (47) p = 0.9836 19 (70) p = 0.1199Vehicle 17 (45) 19 (50) 15 (47)
VRS <1, n (%) (p) Active 20 (62) p = 0.7123 17 (53) p = 0.9836 8 (30) p = 0.1199Vehicle 21 (55) 19 (50) 17 (53)
Secondary criteria
Pruritus VAS, cm, mean (SD) Active 7.7 (0.7) 6.5 (2.6) 5.6 (2.7) 4.4 (2.4)
Vehicle 7.8 (0.7) 6.5 (2.5) 5.9 (2.9) 5.6 (2.9)
SCORAD, mean (SD) Active 35 (5.0) 38.3 (15.0)
p = 0.2128
29.2 (12.6) p = 0.2504Vehicle 35.2 (5.4) 34.3 (12.5) 32.9 (12.7)
aVerbal rating scale (VRS) ≥2: primary criterion i.e. number of subjects presenting at least 2 grades reduction from baseline to week 4 on the item itch intensity 
of the 5-point VRS; VRS ≥1 or <1: revised primary criteria to determine potential significant differences.
VAS: visual analogue scale; SD: standard deviation; SCORAD: Scoring Atopic Dermatitis.
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duration of the study, which might also have influen-
ced the outcome. Application of moisturizers has been 
reported to be able to decrease symptoms and signs of 
AD, including pruritus (12). Finally, in human studies, 
an anti-pruritic effect has so far been shown only for 
sertaconazole in dermatoses associated with fungal 
infections, e.g. seborrhoeic dermatitis, head and neck 
dermatitis with involvement of Malassezia, tinea pedis 
or vaginal candidiasis. This suggests that the outcome 
of the study could have been different if only fungus-
infected AD cases had been included in the study. 
In conclusion, no significant anti-pruritic effect can be 
expected from sertaconazole 2% cream in subjects with 
mild to moderate stable AD. However, it is not known 
if higher concentrations of sertaconazole or different 
formulations have a different effect. The anti-pruritic 
effect reported in the treatment of fungal infections is 
probably linked to its antifungal action. 
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